OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ahn on the Evolution of First-line Treatment Options in HCC

March 7th 2023

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Dr. Awan Discusses Distinguishes Among Available BTK Inhibitors in MCL

March 7th 2023

Farrukh Awan, MD, discusses the potential use of BTK inhibitors in the management of mantle cell leukemia.

Dr. Giralt on the Rationale of the Karmma-3 trial of Ide-cel in R/R Myeloma

March 6th 2023

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Dr. Shah on the Safety of LV20.19 CAR T-cell Therapy in R/R MCL

March 6th 2023

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

Dr. Jain on Unmet Needs in Patients with Myelofibrosis Undergoing Allo-SCT

March 6th 2023

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

Dr. Ahn on the Selection of First-line ICI-Based Combinations in HCC

March 6th 2023

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Dr. Park on the Increasing Use of Biomarker Testing and Radiotheranostics in Prostate Cancer

March 6th 2023

Chandler Park, MD, MSc, FACP, discusses how the emerging field of radiotheranostics and increasing utilization of biomarker testing will improve the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Foote on the Quest to Determine Optimal Sequencing in Late-line mCRC

March 6th 2023

Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.

Dr. Carey on the Response-Guided Therapy in HER2+ Breast Cancer

March 5th 2023

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

Dr. Borgen on the Importance of Addressing Opioid Use in Breast Cancer Care

March 5th 2023

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.

Dr. Chagpar on Financial Toxicity and Disparities in Breast Cancer

March 4th 2023

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the unmet needs regarding financial toxicities for patients with breast cancer.

Dr. Petrylak on Results From the KEYNOTE-921 Trial of Pembrolizumab Plus Docetaxel in mCRPC

March 3rd 2023

Daniel P. Petrylak, MD, discusses efficacy and safety data from the phase 3 KEYNOTE-921 trial of pembrolizumab and docetaxel in metastatic castrate-resistant prostate cancer.

Dr. Chmura on the Management of Oligometastatic Breast Cancer

March 3rd 2023

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Dr. Kalinsky on the Evolving Treatment Landscape and Sequencing ADCs in TNBC

March 3rd 2023

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

Dr. Hunt on Axillary Reverse Mapping in Breast Cancer

March 3rd 2023

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC

March 3rd 2023

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.

Dr. Esserman on the I-SPY2 Trial in Breast Cancer

March 3rd 2023

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Dr. Hassan on the Importance of Accurate Molecular Profiling in Lung Cancer

March 3rd 2023

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

Dr. Saeed on Biomarkers That Influence Treatment Decisions in ESCC

March 2nd 2023

Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.

Dr. Vidal on the Role of Social Determinants of Health in Breast Cancer Care

March 2nd 2023

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.